
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Scottish researchers have discovered a breakthrough treatment they believe will allow thousands of skin-cancer sufferers to treat themselves at home.